BioCardia is a clinical-stage company developing cell therapies for cardiovascular disease, with no approved products and no commercial therapeutic revenue. Its lead program, CardiAMP, is an autologous cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF), targeting patients who remain symptomatic despite optimal drug therapy. The CardiAMP system screens a patient's bone marrow for the right cell composition, then harvests, processes, and delivers those cells directly into the heart muscle via catheter in a single procedure — requiring no immunosuppression and leaving nothing behind. BioCardia is also developing CardiAMP for chronic myocardial ischemia with refractory angina, an allogeneic "off-the-shelf" MSC therapy (CardiALLO) for HFrEF, and an allogeneic MSC therapy for ARDS. BioCardia's Phase III pivotal trial for CardiAMP in HFrEF missed its primary endpoint, but a pre-specified subgroup of sicker patients showed statistically significant benefit; BioCardia is now running a 250-patient confirmatory trial focused on that subgroup while simultaneously pursuing regulatory approval in Japan and exploring a U.S. FDA pathway. The company also owns the Helix delivery catheter and Morph steerable introducer, which it uses in its own trials and licenses to partners. If approved, BioCardia plans to commercialize CardiAMP through a direct cardiology sales force, targeting interventional cardiologists at high-volume hospitals, and expects low cost of goods given point-of-care cell processing. BioCardia operates with roughly $6M in annual cash burn and funds operations through equity issuances.